Published online Jun 30, 2019. doi: 10.13105/wjma.v7.i6.259
Peer-review started: April 15, 2019
First decision: May 8, 2019
Revised: June 2, 2019
Accepted: June 10, 2019
Article in press: June 10, 2019
Published online: June 30, 2019
Although endoscopic retrograde cholangiopancreatography (ERCP) is an important procedure for the diagnosis and treatment of pancreaticobiliary diseases, post-ERCP pancreatitis (PEP) is the most frequent adverse event that can sometimes be fatal. However, prophylactic pancreatic stent (PS) insertion has been performed to prevent PEP in high-risk patients. In some randomized controlled trials (RCTs) and meta-analyses, the efficacy of prophylactic PS insertion has been shown to prevent PEP. In addition, several types of stents have been used to decrease PEP. In this review, we introduce the details of these RCTs and meta-analyses and reveal the specifications for stent placement, for example, the stent diameter and length and the pancreatic region into which the stent should be inserted.
Core tip: Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most frequent adverse event that can sometimes be fatal. Pancreatic stent (PS) insertion is recommended to prevent PEP based on some randomized controlled trials (RCTs) and meta-analyses. Currently, several types of PS have been used. In this review, we introduce these RCTs and meta-analyses and reveal what stent should be used.